Anzeige
Meldung des Tages: Gold-Aktie vor Neubewertung? Über 200 Meter Gold: Warum diese Aktie jetzt in den Fokus der Profis rückt

Cypherpunk Technologies Aktie News

Aktie
WKN:  A3EMJP ISIN:  US52187K2006 US-Symbol:  CYPH Branche:  Biotechnologie Land:  USA
0,9181 $
-0,0035 $
-0,38%
0,7856 € 21.01.26
Depot/Watchlist
Marktkapitalisierung *
42,24 Mio. €
Streubesitz
100,00%
KGV
-
Index-Zuordnung
-

Cypherpunk Technologies News

20.11.25 - wallstreetONLINE Redaktion
Neuer Krypto-Star: Zcash schießt in die Top 10 – Diese Treasury-Firma kauft massiv nach
Die von den Winklevoss-​Brüdern unterstützte Cypherpunk Technologies stockt ihre ZEC-​Bestände auf, während die Kryptowährung in der letzten Woche um 31 Prozent steigt.Zcash (...
12.11.25 - PR Newswire
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results PR Newswire
12.11.25 - PR Newswire
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results PR Newswire
12.11.25 - PR Newswire
Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy
Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy PR Newswire
12.11.25 - PR Newswire
Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy
Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy PR Newswire
20.10.25 - PR Newswire
Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025 PR Newswire
09.10.25 - PR Newswire
Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy PR Newswire
07.10.25 - PR Newswire
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion PR Newswire
07.10.25 - PR Newswire
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion PR Newswire
06.10.25 - PR Newswire
Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy PR Newswire
25.09.25 - PR Newswire
Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025
Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025 PR Newswire
14.08.25 - PR Newswire
Leap Therapeutics Reports Second Quarter 2025 Financial Results
Leap Therapeutics Reports Second Quarter 2025 Financial Results PR Newswire
23.06.25 - PR Newswire
Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives
Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives PR Newswire
13.05.25 - PR Newswire
Leap Therapeutics Reports First Quarter 2025 Financial Results
Leap Therapeutics Reports First Quarter 2025 Financial Results PR Newswire
25.04.25 - PR Newswire
Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting
Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting PR Newswire
15.04.25 - PR Newswire
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-​line Patients with Advanced Microsatellite Stable Colorectal Cancer PR Newswire
26.03.25 - PR Newswire
Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results PR Newswire
26.03.25 - PR Newswire
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study PR Newswire
28.01.25 - PR Newswire
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study PR Newswire

Newssuche

Videos

newspaper
20.01.26 +5,12%
Technical Trading: Gold Zukauf
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »